Pulse Biosciences Management

Management Kriterienprüfungen 2/4

Pulse Biosciences' CEO ist Burke Barrett , ernannt in May 2024, hat eine Amtszeit von weniger als ein Jahr. besitzt direkt 0.02% der Aktien des Unternehmens, im Wert von €210.20K . Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 2.4 Jahre bzw. 6.8 Jahre.

Wichtige Informationen

Burke Barrett

Geschäftsführender

n/a

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts	n/a
Amtszeit als Geschäftsführer	less than a year
Eigentum des Geschäftsführers	0.02%
Durchschnittliche Amtszeit des Managements	2.5yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder	6.8yrs

Jüngste Management Updates

Recent updates

Geschäftsführer

Burke Barrett (60 yo)

less than a year

Amtszeit

Mr. Burke T. Barrett is President & CEO of Pulse Biosciences, Inc. from May 14, 2024 and also serves as its Director since May 2024. Mr. Barrett served as President, Secretary and Director of CardioFocus,...

Führungsteam

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Robert Duggan	Executive Co-Chairman	6.8yrs	US$257.41k	69.46% $ 644.1m
Darrin Uecker	CTO & Director	2yrs	US$5.39m	0.25% $ 2.3m
Mitchell Levinson	Chief Strategy Officer	3.1yrs	US$1.69m	0.22% $ 2.0m
Kevin Danahy	Chief Commercial Officer	less than a year	US$5.86m	0.060% $ 552.8k
Burke Barrett	President	less than a year	keine Daten	0.020% $ 184.2k
Edison Manuel	Vice President of Operations	7.4yrs	keine Daten	keine Daten
Richard Nuccitelli	Chief Science Officer	9.8yrs	keine Daten	keine Daten
Kenneth B. Stratton	General Counsel & Corporate Secretary	3.3yrs	keine Daten	keine Daten
Patty Perla	Vice President of Human Resources	4.7yrs	keine Daten	keine Daten
David Danitz	Senior Vice President of Engineering	3yrs	keine Daten	keine Daten
Gansevoort Dunnington	Chief Medical Officer	1.3yrs	keine Daten	keine Daten
Niv Ad	Chief Science Officer of Cardiac Surgery	less than a year	keine Daten	keine Daten

2.5yrs

Durchschnittliche Betriebszugehörigkeit

59yo

Durchschnittliches Alter

Erfahrenes Management: 6L8Das Führungsteam des Unternehmens gilt als erfahren (2.4 Jahre durchschnittliche Betriebszugehörigkeit).

Vorstandsmitglieder

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Robert Duggan	Executive Co-Chairman	6.8yrs	US$257.41k	69.46% $ 644.1m
Darrin Uecker	CTO & Director	9yrs	US$5.39m	0.25% $ 2.3m
Burke Barrett	President	less than a year	keine Daten	0.020% $ 184.2k
Richard van den Broek	Independent Director	4.1yrs	US$208.89k	0% $ 0
Paul LaViolette	Independent Co-Chairman of the Board	less than a year	keine Daten	keine Daten
Mahkam Zanganeh	Independent Director	7.6yrs	US$173.00k	1.33% $ 12.3m
Manmeet Soni	Lead Independent Director	6.8yrs	US$180.07k	0% $ 0

6.8yrs

Durchschnittliche Betriebszugehörigkeit

58yo

Durchschnittliches Alter

Erfahrener Vorstand: 6L8Die Vorstandsmitglieder gelten als erfahren (6.8 Jahre durchschnittliche Amtszeit).

Pulse Biosciences Management

Management Kriterienprüfungen 2/4

Wichtige Informationen

Jüngste Management Updates

Pulse Biosciences, Inc. Appoints Paul LaViolette to Its Board of Directors

Shelley D. Spray Does Not Stand for Reelection from the Board of Pulse Biosciences, Inc

President & CEO recently bought €79k worth of stock

Pulse Biosciences, Inc Announces CEO Changes

Pulse Biosciences, Inc., Annual General Meeting, Jun 06, 2024

Executive Chairman recently bought €1.0m worth of stock

Recent updates

Pulse Biosciences, Inc. announced delayed 10-Q filing

Pulse Biosciences, Inc. Appoints Paul LaViolette to Its Board of Directors

Pulse Biosciences, Inc. Announces Successful Treatment of Patients in First-in-Human Study with its Nano-PFA Cardiac Surgery System

Pulse Biosciences, Inc. to Report Q2, 2024 Results on Aug 12, 2024

Pulse Biosciences, Inc. has filed a Follow-on Equity Offering in the amount of $60 million.

Pulse Biosciences, Inc. has filed a Follow-on Equity Offering in the amount of $60 million.

Pulse Biosciences, Inc. Announces Receipt of FDA Breakthrough Device Designation for CellFX® nsPFA Cardiac Surgery System for the Treatment of Atrial Fibrillation

Pulse Biosciences, Inc.(NasdaqCM:PLSE) dropped from Russell Small Cap Comp Value Index

Shelley D. Spray Does Not Stand for Reelection from the Board of Pulse Biosciences, Inc

President & CEO recently bought €79k worth of stock

Pulse Biosciences, Inc Announces CEO Changes

Pulse Biosciences, Inc. Announces First U.S. Procedure with the CellFX nsPFA Percutaneous Electrode System

New major risk - Financial position

New major risk - Financial position

Pulse Biosciences, Inc. to Report Q1, 2024 Results on May 07, 2024

Pulse Biosciences, Inc., Annual General Meeting, Jun 06, 2024

Pulse Biosciences, Inc. to Report Q4, 2023 Results on Mar 28, 2024

Pulse Biosciences, Inc. Announces FDA 510(K) Clearance for its CellFX nsPFA Percutaneous Electrode System

Pulse Biosciences Files 510(K) Submission with U.S. FDA for its CellFX nsPFA Cardiac Clamp

Pulse Biosciences, Inc. Announces First-In-Human Procedures with its Novel CellFX Nanosecond Pulsed Field Ablation Cardiac Catheter

Executive Chairman recently bought €1.0m worth of stock

Pulse Biosciences, Inc. Announces Filing of Premarket Notification 510(k) to U.S. Food and Drug Administration for its Novel CellFX nsPFA Percutaneous Electrode

Chief Strategy Officer recently bought €97k worth of stock

Pulse Biosciences, Inc. to Report Q3, 2023 Results on Nov 13, 2023

Pulse Biosciences, Inc. Appoints Dr. Niv Ad as Chief Science Officer, Cardiac Surgery

New major risk - Revenue and earnings growth

Pulse Biosciences, Inc. to Report Q2, 2023 Results on Aug 10, 2023

Pulse Biosciences, Inc. Appoints f Gansevoort 'Gan' Dunnington, M.D. as Its Chief Medical Officer

Pulse Biosciences, Inc. Announces Resignation of Sandra Gardiner as Chief Financial Officer

Pulse Biosciences, Inc. to Report Q3, 2022 Results on Nov 10, 2022

Chief Strategy Officer & Director recently bought €72k worth of stock

Pulse Biosciences Announces Positive Clinical Data on Nano-Pulse Stimulation Procedure for Low-Risk Basal Cell Carcinoma Lesions

Pulse Biosciences, Inc. Announces FDA 510(k) Clearance for the Treatment of Sebaceous Hyperplasia

Pulse Biosciences, Inc. Announces Executive Changes

Pulse Biosciences, Inc. Receives FDA 510(K) Clearance of Expanded Energy Settings for Use with the CellFX System

Pulse Biosciences, Inc. to Report Q2, 2022 Results on Aug 10, 2022

Pulse Biosciences, Inc.(NasdaqCM:PLSE) dropped from Russell 2000 Dynamic Index

Pulse Biosciences, Inc. has completed a Composite Units Offering in the amount of $15 million.

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Pulse Biosciences, Inc

Pulse Biosciences, Inc., Annual General Meeting, May 19, 2022

Pulse Biosciences, Inc. to Report Q4, 2021 Results on Mar 31, 2022

Glancy Prongay & Murray LLP Files Securities Fraud Lawsuit Against Pulse Biosciences, Inc

Pulse Biosciences Announces the Appointment of Kevin Danahy as Chief Commercial Officer

Pulse Biosciences, Inc Provides an Update on Recent FDA 510(k) Submission

Pulse Biosciences, Inc. Provides Revenue Guidance for the Fourth Quarter 2021

Forecast to breakeven in 2024

Independent Chairman of the Board recently bought €42m worth of stock

Pulse Biosciences, Inc. Announces First CellFX Procedure Performed in Canada

Pulse Biosciences Announces Health Canada Approval for CellFX® System

Pulse Biosciences® Presents Clinical Study Results of Nano-Pulse Stimulation™ Technology to Clear Benign Lesions at the American Society for Laser Medicine and Surgery (ASLMS) 2021 Virtual Annual Conference

Pulse Biosciences Announces First CellFX Procedures

Pulse Biosciences Announces Start of Controlled Launch of the CellFX System®

Pulse Biosciences, Inc. to Report Q4, 2020 Results on Feb 22, 2021

Pulse Biosciences, Inc. Announces FDA Clearance for the CellFX® System

New 90-day high: €23.60

Pulse Biosciences Updates on CellFX System Regulatory and Clinical Study Progress

New 90-day high: €19.30

New 90-day high: €15.20

Pulse Biosciences, Inc. to Report Q3, 2020 Results on Nov 09, 2020

Pulse Biosciences Announces Presentation of Clinical Results Using Nano-Pulse Stimulation Technology for the Clearance of Skin Lesions at the American Society for Dermatologic Surgery Virtual Annual Meeting

Pulse Biosciences, Inc. Announces FDA IDE Approval and Initiation of Sebaceous Hyperplasia Study

Pulse Biosciences, Inc. Announces the Company Is Not Reasonably Estimate the Future Impact to the Operations and Financial Results

Geschäftsführer

Amtszeit

Führungsteam

Durchschnittliche Betriebszugehörigkeit

Durchschnittliches Alter

Vorstandsmitglieder

Durchschnittliche Betriebszugehörigkeit